AstraZeneca PLC (AZN.CA) Latest Company News

Aug 20, 2026, 10:04 UTC
Ingrid Zhang, Chief Commercial Officer International at Novartis, decided to leave the company to pursue external opportunities, announced via an internal memo on August 19, 2026.
Source:
- finance.sina.cn
Aug 20, 2026, 08:55 UTC
AstraZeneca's Ravulizumab received approval in China for a third indication, treating paroxysmal nocturnal hemoglobinuria (PNH), as shown on the NMPA website.
Source:
- finance.sina.cn
Aug 18, 2026, 12:23 UTC
On August 18, 2026, Yingte Group and Hangzhou PICC signed a strategic cooperation agreement to jointly launch a provincial exclusive specialty drug commercial insurance product called 'Yingte-PICC Yao Kangbao'.
Source:
- finance.sina.cn
Aug 17, 2026, 22:00 UTC
The UK government announced on August 12 that it is investing 22 million pounds, including 20 million pounds for a new Pre-clinical Translational Models Hub in Cambridge, to grow miniature human organs from NHS patients' cells for drug testing.
Source:
- medicaldaily.com
Aug 17, 2026, 13:22 UTC
AstraZeneca discontinued a late-stage trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer patients lacking PD-L1, following a data monitoring committee recommendation.
Source:
- statnews.com
Aug 17, 2026, 06:28 UTC
AstraZeneca announced on Monday that it is discontinuing a late-stage trial testing volrustomig plus chemotherapy in patients with metastatic non-small cell lung cancer.
Source:
Aug 17, 2026, 06:19 UTC
AstraZeneca announced the official launch of Tezspire (tezepelumab) in China on August 17, 2026.
Source:
- finance.sina.cn
Aug 10, 2026, 15:00 UTC
A London-based drugmaker (AstraZeneca) announced plans to invest US$30 billion in U.S. research and development and supply chain infrastructure over five years.
Source:
- bnnbloomberg.ca
Aug 5, 2026, 23:01 UTC
The UK government expanded its fast-track research visa program, allowing over 100 UK companies including AstraZeneca and Jaguar Land Rover to bring in workers, aiming to capitalize on US President Donald Trump's immigration crackdown.
Source:
Aug 5, 2026, 14:01 UTC
AstraZeneca shares rose about 6% on Wednesday after Reuters reported there are no merger discussions with Bristol Myers Squibb, easing investor concerns.
Source:
- finance.yahoo.com
Aug 5, 2026, 09:51 UTC
CSPC Group received a US$10 million milestone payment from AstraZeneca on 5 August 2026 under the strategic research and development collaboration agreement, related to AstraZeneca's exercise of the license option for one of the PCC projects.
Source:
Aug 5, 2026, 08:35 UTC
CSPC Group and AstraZeneca signed a joint venture contract to establish a joint venture.
Source:
Aug 4, 2026, 10:15 UTC
SOPHiA GENETICS announced a global collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision oncology therapies.
Source:
- prnewswire.com
Aug 3, 2026, 10:09 UTC
AstraZeneca announced the official launch of its innovative drug Imjudo (tremelimumab) in China, for use in combination with Imfinzi (durvalumab) as first-line treatment for adult patients with advanced or unresectable hepatocellular carcinoma.
Source:
- finance.sina.cn
Aug 2, 2026, 19:36 UTC
AstraZeneca has held talks with Bristol Myers Squibb about a potential merger, as reported by the Financial Times on Sunday.
Source:
Jul 31, 2026, 08:00 UTC
AstraZeneca and Daiichi Sankyo's Datroway was approved in the European Union as monotherapy for first-line treatment of metastatic triple-negative breast cancer patients not eligible for immunotherapy.
Source:
- finanznachrichten.de
Jul 30, 2026, 09:00 UTC
AstraZeneca reversed its decision to remove Zoladex from the Australian Pharmaceutical Benefits Scheme and will now provide the drug free of charge to patients with no suitable alternative, with no end date.
Source:
- sbs.com.au
Jul 29, 2026, 19:00 UTC
AstraZeneca announces it will provide Zoladex (goserelin 3.6mg implant) to eligible women in Australia free of charge indefinitely, reversing a planned withdrawal from the PBS and private market.
Source:
- abc.net.au
Jul 29, 2026, 00:00 UTC
Fortrea Holdings Inc. appointed David Smith as Interim Chief Financial Officer and principal financial officer, effective July 27, 2026.
Jul 27, 2026, 20:50 UTC
European stocks closed flat on Monday, with the Stoxx 600 index at 644.52 points, as gains from easing US-Iran tensions and falling oil prices were offset by losses in technology stocks.
Source:
- sana.sy
Jul 27, 2026, 11:51 UTC
MegaStone Biologics received a full upfront payment of $420 million from AstraZeneca on May 29, 2026, and recognized part of it as revenue.
Source:
- wap.eastmoney.com
Jul 27, 2026, 09:24 UTC
CSPC Innovation expects to turn a profit in the first half of 2026, achieving a high level of profitability.
Source:
- finance.sina.cn
- wap.eastmoney.com
Jul 27, 2026, 09:00 UTC
AstraZeneca announced an increased interim dividend of $1.06 per share for Q2 2026 and intends to raise the annual dividend to $3.30 per share for FY 2026.
Source:
- finanznachrichten.de
- rttnews.com
Jul 27, 2026, 07:01 UTC
AstraZeneca announced that its rare disease drug Ultomiris failed a late-stage trial in patients with a blood vessel complication following a stem cell transplant.
Source:
- reuters.com
Jun 29, 2026, 14:55 UTC
AstraZeneca's Datroway received a positive CHMP opinion, moving closer to a first-line EU approval for triple-negative breast cancer.
Source:
- zacks.com
- zacks.com

← PreviousPage 2Next →

AZN.CA

Ingrid Zhang, Chief Commercial Officer International at Novartis, decided to leave the company to pursue external opportunities, announced via an internal memo on August 19, 2026.

AstraZeneca's Ravulizumab received approval in China for a third indication, treating paroxysmal nocturnal hemoglobinuria (PNH), as shown on the NMPA website.

On August 18, 2026, Yingte Group and Hangzhou PICC signed a strategic cooperation agreement to jointly launch a provincial exclusive specialty drug commercial insurance product called 'Yingte-PICC Yao Kangbao'.

The UK government announced on August 12 that it is investing 22 million pounds, including 20 million pounds for a new Pre-clinical Translational Models Hub in Cambridge, to grow miniature human organs from NHS patients' cells for drug testing.

AstraZeneca discontinued a late-stage trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer patients lacking PD-L1, following a data monitoring committee recommendation.

AstraZeneca announced on Monday that it is discontinuing a late-stage trial testing volrustomig plus chemotherapy in patients with metastatic non-small cell lung cancer.

AstraZeneca announced the official launch of Tezspire (tezepelumab) in China on August 17, 2026.

A London-based drugmaker (AstraZeneca) announced plans to invest US$30 billion in U.S. research and development and supply chain infrastructure over five years.

The UK government expanded its fast-track research visa program, allowing over 100 UK companies including AstraZeneca and Jaguar Land Rover to bring in workers, aiming to capitalize on US President Donald Trump's immigration crackdown.

AstraZeneca shares rose about 6% on Wednesday after Reuters reported there are no merger discussions with Bristol Myers Squibb, easing investor concerns.

CSPC Group received a US$10 million milestone payment from AstraZeneca on 5 August 2026 under the strategic research and development collaboration agreement, related to AstraZeneca's exercise of the license option for one of the PCC projects.

CSPC Group and AstraZeneca signed a joint venture contract to establish a joint venture.

SOPHiA GENETICS announced a global collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision oncology therapies.

AstraZeneca announced the official launch of its innovative drug Imjudo (tremelimumab) in China, for use in combination with Imfinzi (durvalumab) as first-line treatment for adult patients with advanced or unresectable hepatocellular carcinoma.

AstraZeneca has held talks with Bristol Myers Squibb about a potential merger, as reported by the Financial Times on Sunday.

AstraZeneca and Daiichi Sankyo's Datroway was approved in the European Union as monotherapy for first-line treatment of metastatic triple-negative breast cancer patients not eligible for immunotherapy.

AstraZeneca reversed its decision to remove Zoladex from the Australian Pharmaceutical Benefits Scheme and will now provide the drug free of charge to patients with no suitable alternative, with no end date.

AstraZeneca announces it will provide Zoladex (goserelin 3.6mg implant) to eligible women in Australia free of charge indefinitely, reversing a planned withdrawal from the PBS and private market.

Fortrea Holdings Inc. appointed David Smith as Interim Chief Financial Officer and principal financial officer, effective July 27, 2026.

European stocks closed flat on Monday, with the Stoxx 600 index at 644.52 points, as gains from easing US-Iran tensions and falling oil prices were offset by losses in technology stocks.

MegaStone Biologics received a full upfront payment of $420 million from AstraZeneca on May 29, 2026, and recognized part of it as revenue.

CSPC Innovation expects to turn a profit in the first half of 2026, achieving a high level of profitability.

AstraZeneca announced an increased interim dividend of $1.06 per share for Q2 2026 and intends to raise the annual dividend to $3.30 per share for FY 2026.

AstraZeneca announced that its rare disease drug Ultomiris failed a late-stage trial in patients with a blood vessel complication following a stem cell transplant.

AstraZeneca's Datroway received a positive CHMP opinion, moving closer to a first-line EU approval for triple-negative breast cancer.